Vivet Therapeutics
Vivet Therapeutics - innovative gene therapy treatments for orphan diseasesVivet TherapeuticsVivet Therapeutics

innovative gene therapy treatments for orphan diseases

  • About us
    • Our DNA
    • Board members
    • Our leadership
    • Partners
  • Pipeline
    • VTX-801 – Wilson’s disease
    • > VTX-801 in Wilson disease – GATEWAY – Phase 1/2 Clinical Trial
    • VTX-802 & VTX-803 – PFIC
    • VTX-804 – Citrullinemia Type 1
  • Investors
  • News
  • Events
  • Patients & Families
    • Patient advocacy
    • Patient & Families ressources
    • Compassionate Use and Expanded Access
  • Work at Vivet

Author Archives: Constance Gatbois

Vivet Therapeutics   →  Articles by: Constance Gatbois
06
Nov
AASLD
Date 6 November 2023
Categories Events

AASLD – The Liver Meeting  in Boston

Vivet Therapeutics is pleased to join AASLD - The Liver Meeting  in Boston, MA this year.

Meet with Vivet Therapeutics for an update on the GATEWAY gene therapy clinical trial for Wilson disease – booth B908
Read More
Author Constance Gatbois
24
Oct
ESGCT Congress
Date 24 October 2023
Categories Events

ESGCT’s 30th Annual Congress in Brussels

Excited to kick off ESGCT's 30th Annual Congress in Brussels today!

Join Vivet's New Programs and Innovation Lead @Nicholas Weber, Ph.D. as he presents on the topic "Gene Therapy for Metabolic Diseases" on 25 October at 2:30 pm.
Read More
Author Constance Gatbois
23
Oct
ESGCT2023
Date 23 October 2023
Categories News

Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress

Paris, France, October 23, 2023 (GLOBE NEWSWIRE) – Vivet Therapeutics (“Vivet”), a clinical- stage biotechnology company
Read More
Author Constance Gatbois
20
Oct
wda conference
Date 20 October 2023
Categories Events

Wilson Disease Association’s Annual Conference

Vivet Therapeutics is delighted to sponsor and present at @Wilson Disease Association's Annual Conference for patients and caregivers. Be sure to tune in to the presentation of CMO Bernard Benichou, MD, Ph.D, and Patient Advocate Lori McKenna Gorski!
Read More
Author Constance Gatbois

Last news

  • ESGCT2023
    Vivet Therapeutics Announces Presentations at Upcoming European Society of Gene and Cell Therapy (ESGCT) 2023 Annual Congress23 October 2023
  • Vivet Therapeutics awarded with the Prix Galien MedStartup in New York28 October 2021
  • GATEWAY clinical trial for Wilson Disease has now its website7 September 2021
  • VTX‐801 Receives U.S. FDA Fast Track Designation for the Treatment of Wilson Disease12 August 2021
  • Gene Therapy aims to be a one-time treatment that may stop or slow the progression of Wilson disease8 July 2021
All NEWS

Last events

  • AASLD
    AASLD – The Liver Meeting  in Boston6 November 2023
  • ESGCT Congress
    ESGCT’s 30th Annual Congress in Brussels24 October 2023
  • wda conference
    Wilson Disease Association’s Annual Conference20 October 2023
  • Vivet presenting during the 6th annual Gene Therapy for Rare Disorders in Boston20 March 2023
  • Vivet presenting at the EPA World Congress in Amsterdam20 March 2023
  • Vivet attending World Orphan Drug Congress 2022 in Sitjes14 November 2022
All EVENTS

About us

  • Our DNA
  • Board members
  • Our leadership
  • Partners

Pipeline

  • VTX-801 – Wilson’s disease
  • > VTX-801 in Wilson disease – GATEWAY
  • VTX-802 & VTX-803 – PFIC
  • VTX-804 – Citrullinemia Type 1

Patients & Families

  • Patient advocacy
  • Patient & Families ressources
  • Compassionate Use and Expanded Access
  • News
  • Events
  • Investors
  • Work at Vivet
  • Contact